Eyenovia, Inc. announced that the FDA has approved Eyenovia?s Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.736 USD | +6.02% | -1.33% | -64.62% |
May. 15 | Transcript : Eyenovia, Inc., Q1 2024 Earnings Call, May 15, 2024 | |
May. 15 | Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.62% | 37.4M | |
+39.22% | 727B | |
+30.57% | 592B | |
-7.85% | 347B | |
+15.48% | 319B | |
-0.12% | 274B | |
+12.55% | 238B | |
+6.65% | 204B | |
-6.09% | 203B | |
-3.37% | 160B |
- Stock Market
- Equities
- EYEN Stock
- News Eyenovia, Inc.
- Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production